Antifungal Properties of Dracaena cinnabari Resin Extracts Against Candida albicans
Rola Ali-Saeed1*, Aied M. Alabsi2, Siti Sufiah Shaherah binti Zainudin1, Nur Nadhirah binti Harun1, Lee Min Quan1, Maged A. Al-Garadi3, Siddig Ibrahim abdelwahab4, Atif Amin Baig2, Antony V Samrot 5, Vetriselvan Subramaniyan6, Ismail, Muhamad Fareez7
Journal of Angiotherapy 8(7) 1-6 https://doi.org/10.25163/angiotherapy.879728
Submitted: 23 May 2024 Revised: 18 July 2024 Published: 25 July 2024
Abstract
Background: Candida albicans is the most prevalent fungal pathogen in humans, capable of causing a range of clinical infections from mucocutaneous conditions like oral thrush to life-threatening systemic diseases. While Candida species are typically part of the normal oral flora in about 75% of the global population, the rising resistance to antifungal drugs has become a significant concern. This highlights the urgent need to explore alternative antimicrobial agents, including natural phytochemicals derived from plants, as potential substitutes for synthetic chemicals to address the growing issue of antifungal resistance. Methods: This study aimed to evaluate the antifungal properties of Dracaena cinnabari resin extracts (methanol and water) against Candida albicans. The antifungal activity was assessed using the direct contact agar diffusion test, while the minimal inhibitory concentration (MIC) of the extracts was determined through the broth dilution method. Results: The antifungal susceptibility tests demonstrated that C. albicans was susceptible to both methanol and water extracts of D. cinnabari resin, with zones of inhibition measuring 32.2 ± 0.8 mm and 29.0 ± 1.1 mm, respectively. The MIC values ranged between 2.50 and 5.00 mg/mL for both extracts. Conclusion: The antifungal effectiveness of D. cinnabari resin extracts was comparable to that of the miconazole control, showing significant potential as a natural treatment option against Candida albicans. These findings suggest that Dracaena cinnabari resin could play a valuable role in the treatment and management of candidiasis, particularly oral candidiasis.
Keywords: Dracaena cinnabari, Candida albicans, Antifungal resistance, Natural products, Oral candidiasis
References
Abu-Taleb A.Y., Alzowahi F A.M.,Tukaram A., K., Shaikh R.U. (2013). Invitro evaluation of antimicrobial and antioxidant activity of Dragon’s blood tree
(Dracaena cinnabari Balf.f.) of Socotra Island (Yemen). Journal of Coastal Life Medicine 1(2), pp.123-129.
Ansari, M., Al-Ghamdi, A., Al-Waili, N., Adgaba, N., Khan, K. and Amro, A. (2021).
Antimicrobial activity of Dracaena cinnabari resin from Soqotra Island on
multi drug resistant human pathogens. African Journal of Traditional, Complementary and Alternative Medicines. 13(1):123-127.
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., . . . Stuppner, H. (2015). Discovery and Resupply of Pharmacologically active plant-derived natural products: A review. Biotechnology Advances, 1582 - 1614.
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., International Natural Product Sciences Taskforce, & Supuran, C. T. (2021). Natural Products in Drug Discovery: Advances and Opportunities. Nature Reviews Drug Discovery, 200.
David L Moyes, Jonathan P Richardson & Julian R Naglik (11 June 2015) Candida albicans-epithelial Interactions and Pathogenicity Mechanisms: Scratching The Surface.
David W. Williams, Rachael P. C. Jordan, Xiao-Qing Wei, Carlos T. Alves, Matt P. Wise, Melanie J. Wilson & Michael A. O. Lewis (October 21, 2013) Interactions of Candida albicans With Host Epithelial Surfaces, Journal of Oral Microbiology, 5:1, 22434
Fesharaki S.H., Haghan I., Mousavi B., Kargar M. L., Boroumand M., Anvari M. S., Abbasi K., Meis J.F., and Badali H. (2013). Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser Journal of Medical Microbiology,62, 1763–1767.
François L. Mayer, Duncan Wilson & Bernhard Hube (2013). Candida albicans
pathogenicity mechanisms, Virulence, 4:2, 119-128.
Freire, J. P., Oliveira Júnior, J. d., Figueredo Silva, D. d., Sousa, J. d., Guerra, F. S., & Oliveira Lima, E. d. (2017). Antifungal Activity of Essential Oil against Candida albicans Strains Isolated from Users of Dental Prosthese. Evidence-Based Complementary and Alternative Medicine (Hindawi).
Hovijitra, R.S., Choonharuangdej, S., & Srithavaj, T. (2016). Effect of Essential Oils
Prepared from Thai Culinary Herbs on sessile Candida albicans cultures. Journal
of Oral Science, 365-371.
Hubálková, I., 2011. Prediction of Dragon's Blood Tree (Dracaena Cinnabari Balf.)
Stand Sample Density on Soqotra Island. Journal of Landscape Ecology, 4(2).
Ibraheam, I., Hussein, H. and Hameed, I., 2018. Bioactivities, Characterization, and Therapeutic Uses of Dracaena cinnabari. International Journal of Pharmaceutical Quality Assurance, 9(01), pp.11-14.
Irene Heredero-Bermejo, Natalia Gómez-Casanova, Sara Quintana, Juan Soliveri, Francisco Javier de la Mata, Jorge Pérez-Serrano, Javier Sánchez-Nieves and José Luis Copa-Patiño, (25 September 2020), In Vitro Activity of Carbosilane Cationic Dendritic
Molecules on Prevention and Treatment of Candida Albicans Biofilms.
Judith Berman, (2012). Current Biology 22 No 16, 620.
Koo H., Andes D.R., Krysan D.J. (2018). Candida–streptococcal interactions in biofilm associated oral diseases. PLoS Pathog. 14(12) 1-7.
Li, Y., Wan, Z., Liu, W., and Li, R. (2015). Synergistic activity of chloroquine
with fluconazole against fluconazole-resistant isolates of Candida species.
Antimicrob. Agents Chemother. 59, 1365–1369. doi: 10.1128/AAC.04417-14
Lopusiewicz, L., & Mizielinska, M. (2017). Antifungal Activity of PLA Foils Covered with Ethylocelulose Containing Essential Oils. World News of Natural Sciences, 27-32.
Martinna Bertolini, Amit Ranjan, Angela Thompson, Patricia I. Diaz, Takanori Sobue, Kendra Maas and Anna Dongari-Bagtzoglou, (April 22, 2019) Candida albicans Induces Mucosal Bacterial Dysbiosis That Promotes Invasive Infection.
Matteo Bassetti, Elda Righi, Philippe Montravers and Oliver A. Cornely (2018). What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead. J Antimicrob Chemother. 2018 ; 73: i14–i25.
Newman, D. J., & Cragg, G. M. (2020). Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. Journal of Natural Products, 770 - 803.
Okonkwo E. C., Alo M. N., Nworie O., Orji J. O., Agah M. V (2013). Prevalence of Oral Candida Albicans Infection in HIV Sero-Positive Patients in Abakaliki. American Journal of Life Sciences. 1, 2, 72-76.
Owasu-Boadi, E., Essuman, M. A., Mensah, G., Ayimbissa, E. A., & Boye, A. (2021). Antimicrobial Activity against Oral Pathogens Confirms the Use of Musa paradisiaca Fruit Stalk in Ethnodentistry. Evidence Based Complementary and Alternative Medicine, 1-9.
Quan, H., Cao, Y. Y., Xu, Z., Zhao, J. X., Gao, P. H., Qin, X. F., et al. (2006). Potent
in vitro synergism of fluconazole and berberine chloride against clinical isolates
of Candida albicans resistant to fluconazole. Antimicrob. Agents Chemother. 50,
1096–1099. doi: 10.1128/AAC.50.3.1096-1099.2006
Roberts, J.D., & Caserio, M.C. (2021, March). Natural Products and Biosynthesis. Retrieved from LibreTexts: https://chem.libretexts.org/@go/page/21994
Sakagami, H., & Tomomura, M. (2018). Dental Application of Natural Products. Medicines, 21.
Sanglard D. and Odds F.C. (2002). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. The Lancet Infectious
Diseases 2,, 73-85.
Umme Hani, Hosakote G. Shivakumar, Rudra Vaghela, Riyaz Ali M. Osmani and Atul Shrivastava (2015). Drug Targets. Candidiasis: A Fungal Infection- Current Challenges and Progress in Prevention and Treatment, Infectious Disorders 15,42-52.
Mohamed Al-Fatimi (2018). Ethnobotanical Survey of Dracaena cinnabari and Investigation of the Pharmacognostical Properties, Antifungal and Antioxidant Activity of Its Resin
View Dimensions
View Altmetric
Save
Citation
View
Share